Trial Profile
Lipid Management in Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 06 Mar 2012 Actual patient number (2390) added as reported by ClinicalTrials.gov.
- 06 Mar 2012 Actual end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.
- 11 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.